Aspire Biopharma Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Aspire Biopharma Holdings, Inc. (ASBP) on July 30, 2025, reporting events that occurred on July 24, 2025. The company is an emerging growth company incorporated in Delaware, formerly known as PowerUp Acquisition Corp.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
Significant changes to the Board of Directors and executive leadership occurred effective July 24, 2025:
- CEO Departure: Michael Howe resigned as Director and Chief Executive Officer. The resignation is not due to any disagreement with the Company or Board.
- Interim CEO Appointment: Kraig Higginson, currently Chairman of the Board and former CEO (four-year tenure), was appointed Interim Chief Executive Officer. A search for a permanent CEO is underway.
- Director Resignations: Gary Stein resigned as independent Director and Chairman of the Audit Committee without disagreement. Barbara Sher resigned as a Director citing irreconcilable differences with the Company's policies and direction.
- Board Appointments: Howard Doss was appointed as Director and Chairman of the Audit Committee. Mr. Doss brings extensive experience as a former CFO for PowerUp, Kernel Group Holdings, and Trade Health, Inc.
Outlook, Risks, and Management Commentary
Management commentary indicates the company is actively searching for a permanent CEO with appropriate experience. The filing notes that the resignations of Mr. Howe and Mr. Stein were not due to disagreements, whereas Ms. Sher's departure was attributed to policy and directional differences. No specific financial risks, contingencies, or unusual items were disclosed in this filing.
Key Facts for Investor Verification
- Verify the timeline and status of the search for a permanent CEO following the appointment of the interim leader.
- Confirm the impact of the Audit Committee leadership change on ongoing financial oversight and reporting.
- Monitor for any potential dissenting letter from Barbara Sher regarding the reasons for her resignation, as the company has offered her the opportunity to provide one.
- Review subsequent filings for the first financial results under the new interim leadership structure.